Ayahuasca for Health & Longevity - Quick Reference Sheet

Ayahuasca for Health & Longevity

Created on 09/30/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Sonnet 5.5 – Audit

Ayahuasca is an oral Amazonian plant brew used for psychological, spiritual and health purposes. Evidence is small and mostly psychiatric: one trial with an inactive comparison treatment supports symptom relief in depression that resisted standard treatment, and nothing addresses lifespan, aging markers or long-term disease prevention. Vomiting is the most consistently documented adverse effect. Most serious documented harms involve predisposed people and serotonin-raising medicine combinations. Relevance to longevity is unproven. (Full Review)

Protocol

Research protocol
Single dose, 1 mL/kg
Standardized decoction, quiet dimly lit room, two or more investigators present, after antidepressant washout
Dose composition and ratio
DMT-to-harmine ratio about 1:5
0.36 mg/mL DMT, 1.86 mg/mL harmine, 0.24 mg/mL harmaline, 1.20 mg/mL tetrahydroharmine, ingested together as one decoction
Ceremonial protocol
About 4–6 hours
Group ceremonies led by an experienced facilitator, typically at night with music or chanting, after dietary preparation; church members typically ingest it at least twice per month
Time to effect
Depressive symptoms
By day 1
Antidepressant effects appeared by day 1; durability beyond day 7 was not measured
Mental health in first-time users
1 and 6 months
Improvement at 1 and 6 months in an uncontrolled before-and-after study
Acute effects
30–45 minutes
Onset within 30–45 minutes, peak at 90–120 minutes, resolve by about 240 minutes

Benefits

Contraindications
  • Personal or family history of psychotic disorders such as schizophrenia (absolute)
  • Bipolar disorder, or a personal or family history of mania or hypomania
  • Current use of MAO inhibitor drugs (e.g., phenelzine, tranylcypromine, moclobemide, selegiline)
  • Serotonin-raising antidepressants (SSRIs, SNRIs; e.g., fluoxetine, sertraline, venlafaxine) without adequate washout (at least 2 weeks; longer for long-half-life drugs such as fluoxetine)
  • Uncontrolled hypertension (screening convention: persistently 160/100 mmHg or higher), or myocardial infarction or stroke within the past 90 days
  • Pregnancy and lactation
  • Severe liver impairment (Child-Pugh Class C)
  • Current suicidal risk or a seizure disorder
Key Interactions
  • CYP2D6 substrate drugs (e.g., metoprolol, codeine, tamoxifen, tramadol)
  • CYP3A4 substrate drugs (e.g., atorvastatin, simvastatin, midazolam)
  • Parkinson's disease medicines (levodopa, pramipexole)
  • Lithium
  • Decongestants and stimulants (pseudoephedrine, phenylephrine)
  • Dextromethorphan (cough suppressant, including combination cold medicines)
  • Serotonin-boosting supplements (St John's wort, 5-hydroxytryptophan, L-tryptophan, S-adenosylmethionine)
  • Supplements with additive blood pressure effects (yohimbe, synephrine, high-dose caffeine)
  • Other psychoactive substances (3,4-methylenedioxymethamphetamine [MDMA, ecstasy], cocaine, amphetamines, alcohol, cannabis)
  • Tyramine-rich foods (aged cheese, cured meats, fermented products)

Risk & Side Effects

  • High: Nausea, Vomiting and Diarrhea
  • Medium: Prolonged Psychological Distress; Transient Blood Pressure Elevation; Acute Tachycardia, Tremor and Dizziness
  • Low: Psychotic and Manic Episodes in Predisposed Individuals; Serotonin Toxicity and Fatal Outcomes; Acute Anxiety and Restlessness; Acute Suicidal Behavior
  • Speculative: Harm to Fetal Development; Harmala Alkaloid Toxicity at High Doses; Persisting Perceptual Disturbances

Monitoring

Marker Target Why
Resting blood pressure Below 120/80 mmHg Diastolic pressure rises during ceremonies
Resting heart rate 50–70 beats per minute Captures autonomic load
Sodium 138–142 mmol/L Vomiting and diarrhea cause fluid loss
Potassium 4.0–5.0 mmol/L Vomiting and diarrhea cause electrolyte loss
ALT and AST (liver enzymes) ALT below 25 U/L; AST below 25 U/L The liver clears DMT and harmala alkaloids
hs-CRP Below 1.0 mg/L Optional inflammation marker; fell after dosing in one trial
CYP2D6 metabolizer status No established target; phenotype categories are poor, intermediate, normal, ultrarapid Harmine clearance and interaction risk
Pregnancy test (hCG) Negative Fetal harm in animal studies

Cadence: During the session, blood pressure and heart rate every 30–60 minutes through the peak at 1.5–2 hours; then at 24–48 hours, at 1 week and at 4 weeks; every 3–6 months when the preparation is used repeatedly; electrolytes rechecked only after prolonged vomiting or diarrhea

Qualitative Assessment

  • Mood and anxiety, by a validated questionnaire
  • Sleep quality and energy in the week after
  • Cognitive clarity
  • Persisting perceptual disturbances
  • Suicidal thoughts or unusually elevated mood